Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)

被引：0
|
作者：
Motzer, R. J.
Rini, B., I
McDermott, D. F.
机构：
来源：
LANCET ONCOLOGY | 2019年 / 20卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E559 / E559
页数：1
相关论文
共 50 条
  • [1] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
    Motzer, R. J.
    Rini, B., I
    McDermott, D. F.
    [J]. LANCET ONCOLOGY, 2020, 21 (06): : E304 - E304
  • [2] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
    Motzer, R. J.
    Rini, B., I
    McDermott, D. F.
    [J]. LANCET ONCOLOGY, 2020, 21 (11): : E518 - E518
  • [3] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
    Motzer, Robert
    Rini, Brian, I
    McDermott, David F.
    Frontera, Osvaldo Aren
    Hammers, Hans J.
    Carducci, Michael A.
    Salman, Pamela
    Escudier, Bernard
    Beuselinck, Benoit
    Amin, Asim
    Porta, Camillo
    George, Saby
    Neiman, Victoria
    Bracarda, Sergio
    Tykodi, Scott S.
    Barthelemy, Philippe
    Leibowitz-Amit, Raya
    Plimack, Elizabeth R.
    Oosting, Sjoukje F.
    Redman, Bruce
    Melichar, Bohusiav
    Powles, Thomas
    Nathan, Paul
    Oudard, Stephan
    Pook, David
    Choueiri, Toni K.
    Donskov, Frede
    Grimm, Marc-Oliver
    Gurney, Howard
    Heng, Daniel Y. C.
    Kollmannsberger, Christian K.
    Harrison, Michael R.
    Tamita, Yoshihiko
    Duran, Ignacio
    Gruenwold, Viktor
    McHenry, M. Brent
    Mekan, Sabeen
    Tannir, Nizar M.
    [J]. LANCET ONCOLOGY, 2019, 20 (10): : 1370 - 1385
  • [4] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
    Albiges, Laurence
    Tannir, Nizar M.
    Burotto, Mauricio
    McDermott, David
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    George, Saby
    Kollmannsberger, Christian K.
    Gurney, Howard
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Castellano, Daniel
    Rini, Brian, I
    Choueiri, Toni K.
    Saggi, Shruti Shally
    McHenry, M. Brent
    Motzer, Robert J.
    [J]. ESMO OPEN, 2020, 5 (06)
  • [5] Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
    Tannir, Nizar M.
    Signoretti, Sabina
    Choueiri, Toni K.
    McDermott, David F.
    Motzer, Robert J.
    Flaifel, Abdallah
    Pignon, Jean-Christophe
    Ficial, Miriam
    Frontera, Osvaldo Aren
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Harrison, Michael R.
    Barthelemy, Philippe
    Tykodi, Scott S.
    Kocsis, Judit
    Ravaud, Alain
    Rodriguez-Cid, Jeronimo R.
    Pal, Sumanta K.
    Murad, Andre M.
    Ishii, Yuko
    Saggi, Shruti Shally
    McHenry, M. Brent
    Rini, Brian, I
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (01) : 78 - 86
  • [6] Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
    Powles, T.
    Burotto, M.
    Escudier, B.
    Apolo, A. B.
    Bourlon, M. T.
    Shah, A. Y.
    Suarez, C.
    Porta, C.
    Barrios, C. H.
    Richardet, M.
    Gurney, H.
    Kessler, E. R.
    Tomita, Y.
    Bedke, J.
    George, S.
    Scheffold, C.
    Wang, P.
    Fedorov, V.
    Motzer, R. J.
    Choueiri, T. K.
    [J]. ESMO OPEN, 2024, 9 (05)
  • [7] Efficacy and safety of nivolumab plus ipilimumab (N plus I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.
    Tannir, Nizar M.
    Signoretti, Sabina
    Choueiri, Toni K.
    McDermott, David F.
    Motzer, Robert J.
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Tykodi, Scott S.
    Pal, Sumanta K.
    Gupta, Saurabh
    Lee, Chung-Wei
    McHenry, M. Brent
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [8] Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
    Powles, Thomas
    Plimack, Elizabeth R.
    Soulieres, Denis
    Waddell, Tom
    Stus, Viktor
    Gafanov, Rustem
    Nosov, Dmitry
    Pouliot, Frederic
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Azevedo, Sergio J.
    Borchiellini, Delphine
    McDermott, Raymond S.
    Bedke, Jens
    Tamada, Satoshi
    Yin, Lina
    Chen, Mei
    Molife, L. Rhoda
    Atkins, Michael B.
    Rini, Brian, I
    [J]. LANCET ONCOLOGY, 2020, 21 (12): : 1563 - 1573
  • [9] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER) long-term follow-up results from an open-label, randomised, phase 3 trial
    Motzer, Robert J.
    Powles, Thomas
    Burotto, Mauricio
    Escudier, Bernard
    Bourlon, Maria T.
    Shah, Amishi Y.
    Suarez, Cristina
    Hamzaj, Alketa
    Porta, Camillo
    Hocking, Christopher M.
    Kessler, Elizabeth R.
    Gurney, Howard
    Tomita, Yoshihiko
    Bedke, Jens
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Apolo, Andrea B.
    Choueiri, Toni K.
    [J]. LANCET ONCOLOGY, 2022, 23 (07): : 888 - 898
  • [10] Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
    Choueiri, Toni K.
    Eto, Masatoshi
    Motzer, Robert
    De Giorgi, Ugo
    Buchler, Tomas
    Basappa, Naveen S.
    Mendez-Vidal, Maria Jose
    Tjulandin, Sergei
    Park, Se Hoon
    Melichar, Bohuslav
    Hutson, Thomas
    Alemany, Carlos
    McGregor, Bradley
    Powles, Thomas
    Gruenwald, Viktor
    Alekseev, Boris
    Rha, Sun Young
    Kopyltsov, Evgeny
    Kapoor, Anil
    Gordoa, Teresa Alonso
    Goh, Jeffrey C.
    Staehler, Michael
    Merchan, Jaime R.
    Xie, Ran
    Perini, Rodolfo F.
    Mody, Kalgi
    McKenzie, Jodi
    Porta, Camillo
    [J]. LANCET ONCOLOGY, 2023, 24 (03): : 228 - 238
12345